Anisomycin茴香霉素 JNK activator JNK激活剂 SP600125 CAS NO:22862-76-6

Anisomycin茴香霉素;Flagecidin;Protein synthesis inhibitor蛋白合成抑制剂;JNK activator JNK激活剂;SP600125;CAS NO:22862-76-6;

 货号  产品名称  CAS NO.  规格     
 MZ0701-5MG  Anisomycin茴香霉素          22862-76-6              5mg  
 MZ0701-10MG  Anisomycin茴香霉素  22862-76-6  10mg  
 MZ0701-50MG  Anisomycin茴香霉素  22862-76-6  50mg  
 MZ0701-100MG        Anisomycin茴香霉素  22862-76-6  100mg     

产品描述:

茴香霉素(Anisomycin),来源于灰色链霉菌(Streptomyces griseolus)的吡咯烷抗生素,是一种有效的蛋白合成抑制剂,通过抑制真核生物核糖体的肽酰转移酶活性来发挥作用。据报道能诱导许多细胞的凋亡发生,包括早幼粒细胞白血病细胞、Jurkat细胞、心室肌细胞和结肠腺癌细胞。启动胞内信号和立早基因诱导。

茴香霉素是强效的JNK激活剂,活化MAP激酶(JNK/SAPK和p38/RK)。作为一种有效的信号通路激动剂,选择性引发即刻早期基因诱导的同源性脱敏(c-fos,fosB,c-jun,junB和junD)。茴香霉素(30mg/kg)表现出优于环孢霉素A(MZ2501-10MG)的免疫抑制活性,阻断皮肤移植小鼠的T细胞增殖。

产品特性

 化学名:(2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate
 CAS NO:22862-76-6  
 同义名:Flagecidin; Wuningmeisu C; NSC76712; AI350846; 回香霉素;
 分子式:C14H19NO4
 分子量:265.30 g/mol
 纯度:≥98%
 外观:白色粉末
 溶解性:溶于甲醇、DMSO(≥20mg/ml)、DMF(20mg/ml)

 【注】:“≥”表示该化合物大于等于标示浓度,但饱和浓度未知。

保存与运输方法

      保存:2-8ºC干燥保存,或置于-20ºC长期干燥保存,至少2年有效。

      运输:室温运输。

注意事项

     (1)本品储存液(溶于有机溶剂,比如DMSO)置于≤-20℃保存(一般情况,-20℃1个月有效;-80℃ 6个月有效,除非有特殊说明),避免反复冻融。任何形式的工作液请现配现用,勿保存再用。

     (2)本品对热敏感,易吸潮。保持低温、密封干燥保存。

     (3)本品并非商业化的临床药物,仅用作科研用途,不得用作临床诊断或治疗,不得用于食品或药品,绝对禁止用在人身上。

     (4) 为了您的安全和健康,请穿实验服并戴一次性手套操作。

储存液配制

          质量

溶剂体积

 浓度

 1mg  5 mg   10mg
 1mM  3.7693 mL  18.8466 mL  37.6932 mL   
 5mM  0.7539mL  3.7693 mL  7.5386 mL
 10mM  0.3769 mL  1.8847 mL  3.7693 mL
 50mM  0.0754 mL  0.3769 mL  0.7539mL

使用方法【源自文献,仅作参考】

  文献1,Yan J et al. c-Jun N-terminal kinase activation contributes to reduced connexin43 and development of atrial arrhythmias. Cardiovasc Res. 2013 Mar 1;97(3):589-97. PMID: 23241357

  体外研究(细胞实验):

  细胞类型(Cell types):Mouse atrial myocyte line (HL-1)

  实验方法(Assay):Atrial myocytes were treated with 50 ng/mL anisomycin with or without 2 µmol/L SP600125, or a corresponding amount of the DMSO solvent for 16 or 24 h followed by biochemical or optical   mapping studies.

  体内研究(动物模型):

  动物模型(Animal Model):Young (6 months) and aged (54 months) male New Zealand White rabbits

  实验方法(Assay):LA effective refractory period (AERP) was measured using an S1-S2 pacing protocol and atrial arrhythmias (AT/AF) were induced using burst pacing in open-chest heartsin young rabbits with (n = 4)  or without (n = 5)anisomycin treatment (15 mg/kg, iv, four treatments over 9 days)and aged rabbits without anisomycin treatment (n = 6).

 文献2,Lattal KM et al. Behavioral impairments caused by injections of the protein synthesis inhibitor anisomycin after contextual retrieval reverse with time. Proc Natl Acad Sci U S A. 2004 Mar 30; 101(13):4667-72.    PMID: 15070775

 体内研究(动物模型):

 动物模型(Animal Model):Male C57BL/6 mice (8-12 weeks old)

 配制方法(Formulation):Anisomycin wasdiluted in salineand dissolved in 1 M HCl. The pH was adjusted to≈7 with 1 M NaOH.

 实验方法(Assay):Mice received subcutaneous injections of 50 or 75 mg of anisomycin/kg of body weight or an equivalent volume of saline in the first experiment. Injections in all other experiments were 50 mg/kg of anisomycin or an equivalent volume of saline.

 文献3,Guo Xet al. GSK3β regulates AKT-induced central nervous system axon regeneration via an eIF2Bε-dependent, mTORC1-independent pathway. Elife. 2016 Mar 14;5:e11903.PMID: 26974342.

 体内研究(动物模型):

 动物模型(Animal Model):

 配制方法(Formulation):Anisomycin was dissolved inDMSO to prepare a stock solution anddiluted inPBS before each administration.

 实验方法(Assay):Anisomycin (30 mg/kg body weight)or vehicle was injected subcutaneously daily after optic nerve crush. To inhibit OPP incorporation, anisomycin (50 μg/ml) was injected intravitreally 1 hr before  and together with OPP administration.

 

 货号  产品名称  规格
 MZ0701-5MG  Anisomycin茴香霉素  5mg
 MZ0702-10MG  SP600125 JNK抑制剂  10mg
 MZ0201-10MG  Rapamycin (Sirolimus)雷帕霉素(西罗莫司)  10mg
 MZ2501-10MG  Cyclosporin A (CsA)  环孢霉素A  10mg

注意事项

为了您的安全和健康,请穿实验服并戴一次性手套操作。